NasdaqGM:LGNDPharmaceuticals
Ligand Pharmaceuticals (LGND) Stock Pulls Back As Royalty Profit Strength Meets Valuation Doubts
Ligand Pharmaceuticals stock slipped about 2% after earnings, which might surprise anyone focused on its premium P/E and royalty driven reputation. The headline from this quarter is earnings power. Adjusted diluted earnings per share landed at about US$2.37 on revenue of roughly US$64 million, with royalty revenue doing most of the work.
Coming into the print, shares were already up strongly over the past three months. Today’s pullback looks more like a valuation check rather than a verdict...